Stereotactic radiation therapy is a safe and effective treatment for cancer patients with only one kidney, according to research presented at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas.

Contrary to recent data suggesting African-Americans face a higher mortality risk from prostate cancer than Caucasian men, a new study presented at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting suggests African-American men may have higher cure rates when treated with radiation therapy than Caucasian men.

World's first 85cm 64 and 128 slice wide bore CT unit for oncology

STAMFORD, Conn.—FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, today introduced the FCT Embrace. Powered by Analogic, the FCT Embrace is the world’s first 85cm wide bore computed tomography (CT) imaging unitwith 64 or 128 slice configurations. Optimized for both oncology and radiology applications, the FCT Embrace, combined with other market-leading oncology solutions, offers enhanced and efficient CT Simulation with radiotherapy treatment planning capabilities. The unveiling at booth #3063 during the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting marks Fujifilm’s entry into the CT market, expanding its end-to-end diagnostic imaging product portfolio which is recognized for exceptional imaging at low dose.

A $1.6 million, four-year grant from the National Cancer Institute of the National Institutes of Health (NIH) was awarded to a researcher from Tulane University in Louisiana to develop a prostate cancer scanner that can check whether all traces of cancer have been removed after surgery, according to The Associated Press.

Results of a new randomized, phase II clinical trial have demonstrated an aggressive form of precision radiation therapy can increase the lifespan of oligometastatic cancer patients and doubles how long they can live without cancer, according to the American Society for Radiation Oncology (ASTRO).

Women with a history of cardiotoxicity from previous cancer treatments are around 30 percent more likely to experience clinical congestive heart failure (CHF) before, during or after pregnancy, according to research published ahead of print in the Journal of the American College of Cardiology.

More frequent surveillance imaging does not improve overall survival or post-recurrence survival for patients with non-small cell lung cancer (NSCLC), according to research published in the October issue of Annals of Surgery.